Jci_page_head_homepage_01 Jci_page_head_homepage_02
Yue Si, Chia-Lin Tsou, Kelsey Croft, Israel F. Charo
Published in Volume 120, Issue 4
J Clin Invest. 2010; 120(4):1192–1203 doi:10.1172/JCI40310
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
Expression of functional CCR2 on HSCs and HPCs.

(A) BM HSCs and HPCs were identified by FACS, and the surface expression of CCR2 was quantified. LT-HSCs, defined as LinSca1+c-Kit+IL7RαThy1loCD34 cells. ST-HSCs, defined as LinSca1+c-Kit+IL7RαThy1loCD34+ cells. MPPs, defined as LinSca1+c-Kit+IL7RαThy1CD34+ cells. CMPs, common myeloid progenitors, defined as LinSca1c-Kit+Thy1IL7RαCD34+CD16/32lo cells. GMPs, defined as LinSca1c-Kit+ Thy1IL7RαCD34+CD16/32+ cells. MEPs, megakaryocyte-erythroid progenitors, defined as LinSca1c-Kit+Thy1IL7RαCD34CD16/32 cells. The percentage of CCR2+ cells in each group is indicated and is shown graphically in B. Values are mean ± SD. n = 4 mice per genotype. Similar results were obtained in 5 independent studies. (C) qRT-PCR of CCR2 mRNA in HSCs/HPCs. Total RNA was extracted from HSCs and the indicated HPCs. CCR2 mRNA levels were determined by qRT-PCR and are expressed relative to the level in HSCs (arbitrarily set to 1.0). Values are mean ± SD.